Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02082379 · ClinicalTrials.gov registry record · NA
In-Vivo Evaluation of Nebulized Aerosols Delivered Via Nasal Route
A NA study, sponsored by Arkansas Children's Hospital Research Institute.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
NCT02082379: Completed NA study, sponsored by Arkansas Children's Hospital Research Institute.
NCT02082379 is a NA study that has completed, run by Arkansas Children's Hospital Research Institute. The registered enrollment target is 21 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02082379, a NA study, has completed, sponsored by Arkansas Children's Hospital Research Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
Study Summary
We hypothesize that infant and children will show different levels of acceptance of different interfaces while they receive inhaled therapy. We also hypothesize that children will exhibit different amounts of time with the aerosol well aligned with the nostrils during transnasal aerosol delivery.
Primary Outcome
The recordings will be analyzed by the 2 investigators for acceptance of the patient of the interface (likert scale 1 to 5: 5= Complete acceptance, 4= Accepting most of the time, 3= Accepting/rejecting half of the time, 2= Rejecting most of the time, 1= Complete rejection). The data will be expressed as average of value assigned by each of the 2 researchers. Analysis of variance for repeated measures followed by Tukey test will be used to compare the 2 endpoints. A p value \< 0.05 will be consid
Interventions
- BEHAVIORAL inhaled normal saline using different interfaces.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2014-01 |
| Est. Completion | 2015-02 |
| Phase | NA |
What the finished NCT02082379 record still lists
NCT02082379 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which inhaled normal saline using different interfaces. is the first listed.
NCT02082379 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02082379 about?
NCT02082379 is a clinical study titled "In-Vivo Evaluation of Nebulized Aerosols Delivered Via Nasal Route". We hypothesize that infant and children will show different levels of acceptance of different interfaces while they receive inhaled therapy. We also hypothesize that children will exhibit different amounts of time with the aerosol well aligned with the nostrils during transnasal aerosol delivery.
What is the current status of trial NCT02082379?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2014-01. Estimated completion is 2015-02.
What interventions are being tested in trial NCT02082379?
The interventions under investigation include: inhaled normal saline using different interfaces. (BEHAVIORAL).
Who is sponsoring clinical trial NCT02082379?
This trial is sponsored by Arkansas Children's Hospital Research Institute, which has 97 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02082379's enrollment target sits among peer trials
21 1762nd of 2000 higher than 233 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia